This reports provides a data-driven overview of the current and future competitive landscape in Anxiety therapeutics.
Our Anxiety Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
Synopsis
- In 2022, there will be more than 291 million prevalent cases of anxiety across 16 pharmaceutical markets
- There are three leading marketed drugs for the treatment of anxiety, Viatris is a key player in the disease space
- R&D activity in anxiety is steady, with eight products in Phase III development
- Non-industrial sponsors dominate clinical trial development in anxiety, with the US and China emerging as the key countries for conducting trials in anxiety
- Deals involving partnerships and acquisitions were the two most common types of deals globally
- Most of the upcoming future catalysts in anxiety are related to patent expiries across the US, EU, and Japan
Scope
Our Anxiety Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the Anxiety market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Anxiety market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Table of Contents
1 Preface
List of Tables
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pipeline Drugs Assessment
6 Clinical Trials Assessment
7 Deals Landscape
8 Commercial Assessment
10 Appendix
